Singular Genomics Systems, Inc.

Good day, and thank you for standing by. Welcome to the Singular Genomics Fourth Quarter Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you will need to press star 1 on your telephone. Please be advised that today's conference may be recorded. If you require any further assistance, please press star then 0. I would now like to hand the conference over to your host today, Philip Taylor. Please go ahead.

Thank you, operator.

Presenting today are Singular Genomics founder and chief executive officer, Drew Spaventa, and head of finance, Dalen Meader. Earlier today, Singular Genomics released financial results for the three months and full year ended December 31, 2021. A copy of the press release is available on the company's website. Before we begin, I would like to inform you that comments and responses to your questions during today's call reflect management's view as of today, March 2, 2022 only, and will include forward-looking statements and opinion statements, including predictions, estimates, plans, expectations, and other information. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued earlier today and in our filings with the Securities and Exchange Commission. Our SEC filings can be found on our website or on the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements. We disclaim any obligation to update or revise these forward-looking statements. Please note that this conference call will be available for audio replay on our website at singulargenomics.com on the events page of the news and events section on our investors page. With that, I'll turn the call over to CEO Drew Spaventa.